Effects of Probiotic Ayran on Gingivitis

May 29, 2024 updated by: Cenk Haytac, Cukurova University

Effects of the Use of Probiotics Ayran on Gingival Inflammation: An Experimental Gingivitis Study

Objectives: This study investigates the effects of daily consumption of probiotic ayran drink on gingival inflammation and the development of experimental gingivitis.

Methods: A total of 54volunteer students were included in the present randomized, double-blind, placebo-controlled trial.The participants were divided randomly into two groups; The Control group consisted of 27 participants who consumed placebo ayran, while the 27 participants of the Test group consumed probiotic ayran (containing Lactobacillus acidophilus and Bifidobacterium bifidum) for 42 days twice a day.After 42 days, mechanical plaque control was interrupted for 5 days. The clinical parameters of gingivitis; Plaque index (PI), gingival index (GI), probing bleeding (BOP), probing depth (PPD) were recorded at baseline, day 42 (beginning of experimental gingivitis) and day 47 (the end of experimental gingivitis). At the same time points, gingival crevicular fluid had been collected for analysis of matrix metalloproteinase - 8 (MMP-8).

Study Overview

Detailed Description

The most used and studied probiotics in the periodontal literature are lactobacillus and bifidobacterium. The current study aims to observe the effects of daily ayran consumption containing a probiotic combination of Lactobacillus acidophilus and Bifidobacterium bifidum on plaque development and gingival inflammation in an experimental gingivitis model of healthy individuals. The null hypothesis of this study using of probiotics has no additional benefit for periodontal health.

This study evaluates the effects of daily consumption of ayran containing a probiotic combination of Lactobacillus Acidophilus and Bifidobacterium Bifidum on plaque development and gingival status in healthy individuals with experimental gingivitis.

Study Type

Interventional

Enrollment (Actual)

54

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Adana, Turkey
        • Cukurova university Faculty of Dentistry

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Systemic healthy
  • Subjects with gingivitis defined as a BOP sites ≥ 10% and PD ≤ 3 mm
  • No radiographic bone loss
  • Non-smoking participants

Exclusion Criteria:

  • History of using antibiotics or anti-inflammatory drugs or probiotic preparations or food supplements in the last 6 months,
  • Undergoing orthodontic treatment,
  • Active carious lesions
  • Mouth breathing
  • History of allergy for milk or fermented milk products.
  • Taking medications affecting the gingiva and/or oral mucosa

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Probiotic ayran drink
The participants in this experimental group will use probiotic containing ayran for 42 days and then will be subjected to 5 days of experimental gingivitis.
The test group has received probiotic ayran drink for 6 weeks
Placebo Comparator: Placebo ayran drink
The participants in this control group will use control ayran without probiotics for 42 days and then will be subjected to 5 days of experimental gingivitis.
The control group has received placebo ayran drink for 6 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plaque index
Time Frame: Plaque index will be recorded at baseline, at day 42 and 47
PI was scored from 0 to 5 according to the color change obtained with the Mira-2 solution
Plaque index will be recorded at baseline, at day 42 and 47
Gingival index
Time Frame: Gingival index will be recorded at baseline, at day 42 and 47
GI is graded by visual assessment and mechanical stimulation of the gingival tissues, scoring the gingival condition according to the criteria
Gingival index will be recorded at baseline, at day 42 and 47
Bleeding on probing
Time Frame: BOP will be recorded at baseline, at day 42 and 47
The probing bleeding (BOP) index was determined by the presence/absence of bleeding ≈30 seconds after probing
BOP will be recorded at baseline, at day 42 and 47

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Cenk Haytac, phd, PROFESSOR DOCTOR

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 15, 2023

Primary Completion (Actual)

April 15, 2023

Study Completion (Actual)

June 15, 2023

Study Registration Dates

First Submitted

May 22, 2024

First Submitted That Met QC Criteria

May 29, 2024

First Posted (Actual)

May 31, 2024

Study Record Updates

Last Update Posted (Actual)

May 31, 2024

Last Update Submitted That Met QC Criteria

May 29, 2024

Last Verified

May 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • Cukurova University-1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The data will be shared upon request

IPD Sharing Time Frame

The data is ready and can be shared for two years

IPD Sharing Access Criteria

The data will be shared upon request

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gingivitis

Clinical Trials on probiotic ayran drink

Subscribe